- Updated inclusion criteria to allow for histological evidence of fatty liver within 2 years of - screening and to ensure subjects with cirrhosis or liver disease were not enrolled in the study - Added exclusion criterion (HbA1c > 9% at screening) to ensure subjects with poorly - controlled diabetes were not enrolled in the study - Provided additional nonclinical safety data - Updated data from other clinical studies of GS-9674 - Updated the risk/benefit assessment to communicate the risk for liver injury and provide newly available safety data - Added guidance regarding concomitant use of atorvastatin - Updated the list of prohibited medications based on newly available drug-drug interaction data - Allowed subjects to rescreen once for the study - Revised drug-induced liver injury (DILI) monitoring language to update thresholds, add creatine phosphokinase testing as a requirement for DILI observation, and to clarify study drug stopping rules - Allowed hormonal contraception as a highly effective contraceptive method

-Allowed for a historical liver biopsy consistent with NASH and no documented weight loss > 5% between the date of the liver biopsy and screening to determine eligibility for enrollment - Extended screening period to up to 6 weeks - Lowered screening MRI-PDFF cutoff from ≥ 10% to ≥ 8% for detection of steatosis, and lowered screening MRE cutoff from ≥ 2.90 to ≥ 2.5 kPa for detection of hepatic fibrosis - Removed creatinine clearance inclusion criterion and replaced with criterion specifying a normal serum creatinine level - Added language to clarify that subjects with FibroSURE/FibroTest ≥ 0.75 were eligible for enrollment if a liver biopsy within 12 months of screening excluded cirrhosis. Additionally, direct bilirubin was used instead of total bilirubin in FibroSURE/FibroTest calculations for subjects with Gilbert’s syndrome or hemolysis - Added nonclinical toxicology data to support dosing of subjects beyond 12 weeks - Clarified that study drug should not be administered within 4 hours of dosing with bile acid sequestrants - Provided guidance regarding retesting of exclusionary laboratory analyses during screening and allowed retesting to be performed at the principal investigator’s discretion - Clarified that subjects who failed screening but met the revised inclusion/exclusion criteria were eligible for enrollment